COLLABORATIONS

We are a highly collaborative laboratory and always welcome partnerships across laboratories and disciplines.

%E2%80%8FmicroRNA%20signaling%20for%20website_edited.jpg

DISCOVERY OF PHARMACODYNAMIC MOLECULAR BIOMARKERS FOR STEROIDAL AND ANTI-INFLAMMATORY DRUGS

In collaboration with Dr. Christopher Heier, this work focuses on identifying microRNAs as biomarkers in inflammatory diseases. Specifically, we have defined how anti-inflammatory drugs (steroidal ligand/TNFα inhibitors) affect serum miRNA levels in Inflammatory Bowel Disease patients and in dystrophic mouse muscle after treatment with prednisone or the dissociative steroid, vamarolone (VBP15). Through this work we describe microRNAs that correspond to disease severity, inflammation, and drug response. Moving forward we will utilize these miRNAs to define the efficacy of anti-inflammatory drug treatment in DMD and other inflammatory diseases.

Cell reports logo.jpg

MICRORNA MODULATION TO INCREASE DYSTROPHIN LEVELS IN DUCHENNE AND BECKER MUSCULAR DYSTROPHY

In partnership with ReveraGen Biopharma and Dr. Eric Hoffman, our laboratory has a patent for the therapeutic targeting of dystrophin-targeting microRNAs to increase dystrophin levels in Duchenne and Becker Muscular Dystrophy. 

microRNAs in MG.jpg

MICRORNA REGULATION IN MYASTHENIA GRAVIS

Myasthenia gravis (MG) is a neuromuscular disorder that causes weakness in the skeletal muscles. It occurs when communication between nerve cells and muscles becomes impaired. In collaboration with Dr. Anna Rostedt Punga  we are investigating transcription factors that regulate miRNAs that are dysregated in the serum of Myastenia Gravis patients.